SCHEMBL1778375

SCHEMBL1778375

[2H]C1([2H])CNCCN1CC(=O)Nc1c(C)cccc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.49
DRD4 P21917 1/20 0.47
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
KCNH2 Q12809 3/20 0.46
ADRB1 P08588 2/20 0.46
CYP3A4 P08684 2/20 0.46
ADRA2A P08913 2/20 0.46
CYP2D6 P10635 2/20 0.46
ADRA2B P18089 2/20 0.46
ADRA2C P18825 2/20 0.46
ADRA1A P35348 2/20 0.46
DRD3 P35462 2/20 0.46
HTR2B P41595 2/20 0.46
LMNA P02545 2/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
CHRM3 P20309 2/20 0.46
MLNR O43193 1/20 0.46
NR1I2 O75469 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1777934 0.91 ALDH1A1 (0.57) ALDH1A1DRD4MEN1KMT2AKCNH2
Hydrochloric Acid SCHEMBL8554173 0.88 ALDH1A1 (0.55) ALDH1A1DRD4MEN1KMT2AKCNH2
SCHEMBL9031046 0.82 DRD4 (0.60) ALDH1A1DRD4MEN1KMT2ALMNA
SCHEMBL2327539 0.80 ALDH1A1 (0.64) ALDH1A1DRD4MEN1KMT2AKCNH2
SCHEMBL4034304 0.80 TP53 (0.56) ALDH1A1MEN1KMT2AKCNH2CYP1A2
Pyrrocaine SCHEMBL25718 0.78 MEN1 (0.70) ALDH1A1DRD4MEN1KMT2AKCNH2
SCHEMBL6343148 0.77 ALDH1A1 (0.52) ALDH1A1DRD4MEN1KMT2AKCNH2
SCHEMBL7288776 0.77 POLB (0.74) ALDH1A1MEN1KMT2ALMNACHRM3
SCHEMBL9031042 0.77 ALDH1A1 (0.49) ALDH1A1DRD4MEN1KMT2AKCNH2
Pyrrocaine SCHEMBL10757216 0.76 MEN1 (0.68) ALDH1A1DRD4MEN1KMT2AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943620-B2 Anti-anginal compounds CONCERT PHARMACEUTICALS, INC. (US) 2011-05-17 US disclosed
EP-2139877-B1 DEUTERATED PIPERAZINE DERIVATIVES AS ANTI-ANGINAL COMPOUNDS CONCERT PHARMACEUTICALS INC (US) 2011-05-11 EP disclosed
EP-2139877-A1 DEUTERATED PIPERAZINE DERIVATIVES AS ANTI-ANGINAL COMPOUNDS Concert Pharmaceuticals Inc. (US) 2010-01-06 EP disclosed
US-20080318969-A1 Anti-anginal compounds SUN PHARMACEUTICAL INDUSTRIES, INC. 2008-12-25 US disclosed
WO-2008109175-A1 DEUTERATED PIPERAZINE DERIVATIVES AS ANTI-ANGINAL COMPOUNDS CONCERT PHARMACEUTICALS, INC. (US) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318969-A1 Anti-anginal compounds SQLE, ACSL5, ACSL1 ALDH1A1 523/4885DRD4 2497/4885MEN1 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.